WS
AIM

Wedbush Securities’s AIM ImmunoTech AIM Stock Holding History

Wedbush Securities’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-133
Closed -$29K – 1047
2020
Q3 		$29K Buy
+133
New +$33.2K ﹤0.01% 913
2015
Q3 		– Sell
-1
Closed -$7K – 810
2015
Q2 		$7K Sell
1
-1
-50% -$12.4K ﹤0.01% 724
2015
Q1 		$18K Buy
2
+1
+100% +$12.5K ﹤0.01% 726
2014
Q4 		$19K Sell
1
-1
-50% -$14.9K ﹤0.01% 700
2014
Q3 		$26K Hold
2
– – ﹤0.01% 677
2014
Q2 		$35K Sell
2
-1
-33% -$17.9K 0.01% 644
2014
Q1 		$59K Hold
3
– – 0.01% 599
2013
Q4 		$41K Buy
+3
New +$36.2K 0.01% 568

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

Wedbush Securities's AIM Position: Q4 2020 in Review

Wedbush Securities sold out of AIM ImmunoTech (AIM) in Q4 2020, closing a stake of 133 shares — an estimated $29K sold.

Wedbush Securities first reported a position in AIM in Q4 2013 and held it in 8 quarters. The position peaked at $59K in Q1 2014. 33 funds tracked by Wall St. Rank hold AIM as of Q4 2020.

  • Wedbush Securities reported no remaining AIM ImmunoTech position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 133 AIM ImmunoTech shares in Q4 2020, an estimated $29K.
  • Wedbush Securities first reported a position in AIM ImmunoTech in Q4 2013 and held it in 8 quarters.
  • Wedbush Securities's AIM ImmunoTech position peaked at $59K in Q1 2014.
  • 33 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.